MedTrace Logo

Off-Label AVASTIN (BEVACIZUMAB) For Serosanguinous Maculopathy

NCT00344617 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2007-09-26

No results posted yet for this study

Summary

To assess the use of Avastin for the management of serosanguinous maculopathy

Conditions

  • Choroidal Neovascularisation
  • Polypoidal Choroidal Vasculopathy

Interventions

DRUG

Bevacizumab (tradename: Avastin)

Sponsors & Collaborators

  • Singapore National Eye Centre

    lead OTHER_GOV

Principal Investigators

  • Chong-Lye Ang, FRCOphth · Singapore National Eye Centre

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-06-30
Completion
2008-05-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00344617 on ClinicalTrials.gov